B-cell-targeted therapies in systemic lupus erythematosus - Test2 - elhamkhani - TriplyDB

B-cell-targeted therapies in systemic lupus erythematosus

B-cell-targeted therapies in systemic lupus erythematosus

http://www.wikidata.org/entity/Q37729368

about

B-cell survival factors in autoimmune rheumatic disorders Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines POLYMERIC BIOMATERIALS AND NANOMEDICINES.B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.Critical role of DNA methylation in the pathogenesis of systemic lupus erythematosus: new advances and future challenges.Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Unintended Immunological Consequences of Biologic Therapy.Refractory Sweet's syndrome successfully treated with rituximab.Translating epigenetics into clinic: focus on lupus.PhD7Faster: predicting clones propagating faster from the Ph.D.-7 phage display peptide library.Frontiers in B-cell immunology.BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model.CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.B Cell-Intrinsic Role for IRF5 in TLR9/BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation.Expression of CCR6 on B cells in systemic lupus erythematosus patients.Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.Suppression of interleukin 17 contributes to the immunomodulatory effects of adipose-derived stem cells in a murine model of systemic lupus erythematosus.Expression and Polymorphisms of Lysosome-Associated Protein Transmembrane 5 (LAPTM5) in Patients with Systemic Lupus Erythematosus in a Chinese Population.

P2860

Q26796484-4DC552B9-003D-41A9-B886-A713B21490CB Q35861726-47FA0700-D6E8-4C78-8DC8-4E879297500C Q36376467-D8708FD9-700B-48C3-8A0A-A1E7D79C53DD Q38131034-A7DB01EB-C577-4DB5-B6F0-6119A05320FA Q38197135-48155DA9-8C6A-40A4-B716-F16F430CEF04 Q38289398-4B07A3A1-529D-423A-BC91-2EF6983E4129 Q38747383-B91A2C9B-5BB7-4757-B6CA-5E355EEBE024 Q38871098-9F53EF8D-F0D7-427B-A111-7DE650A7893C Q39534447-34C95592-317F-4621-9210-1E095D45E13F Q41228881-8D4ED5AB-34CA-44BB-AD47-86F7268BAE9A Q42240823-389BAC4F-7C95-4FD8-B43A-1D6AB6BC8567 Q42543051-34E05C0B-27DE-494E-B0BA-AC4FFE9033AD Q47095865-510B0FBA-4BA7-46C6-967C-B13CC50CF776 Q47389712-6CD25965-41C7-4472-833F-79A4E106B477 Q48216696-12D078F7-0ED9-48D5-ABC2-428D242EE6EA Q49163388-4B53B2CC-C29A-49C4-9BEF-085C78220981 Q50586102-C185A64B-4896-442D-AEF0-91A428C9D989 Q50708173-009C58BC-48C1-44DA-BFB7-548459884022 Q51519261-3F260A7C-7309-4C7C-83B8-2B491A53B46D Q53496399-526D470A-FD05-4B6F-9D53-9C59F0740955

P2860

B-cell-targeted therapies in systemic lupus erythematosus

http://www.wikidata.org/entity/Q37729368

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

B-cell-targeted therapies in systemic lupus erythematosus

@en

B-cell-targeted therapies in systemic lupus erythematosus.

@nl

type

label

B-cell-targeted therapies in systemic lupus erythematosus

@en

B-cell-targeted therapies in systemic lupus erythematosus.

@nl

prefLabel

B-cell-targeted therapies in systemic lupus erythematosus

@en

B-cell-targeted therapies in systemic lupus erythematosus.

@nl

P1433

Q37729368-33B49C3D-6584-4C15-86EA-042ACA779492

P1476

Q37729368-FC522680-74CA-4E04-8FF6-17EBC199C4E9

P2093

Q37729368-022365AC-2C4E-42A9-812F-50B0ECAA4736

Q37729368-04D0C84F-9BD4-445B-A9C7-4E257771F246

Q37729368-0E9B13B2-52A8-444B-BC50-C3E23A88C643

Q37729368-881E87DA-58FF-40D2-9BC6-0B3757E52F9E

P2860

Q37729368-05872FED-1D50-4548-953E-3583FC190BF5

Q37729368-0598EC73-CD2C-4EBA-A863-F178E4C90CF0

Q37729368-091EA640-E0BB-418E-A9BF-92A2F06C7ACF

Q37729368-093414B0-EC12-462C-8366-7FBCDDD3B009

Q37729368-0CACAC5C-B1F6-47F9-92EC-0CEBA5FE1BE5

Q37729368-0DDAAE90-5B69-4832-8117-59E80A3849E2

Q37729368-0FDA3593-29AE-4FF5-93C7-F14905718094

Q37729368-1E1D8A3D-F841-40A1-9AD1-7D73193BE9ED

Q37729368-1E7832E9-6DB8-4CFE-8783-D20EFFC45F51

Q37729368-20250262-95A4-49C5-9FF7-3EFBD49FB156

P2888

Q37729368-D44A7C6B-146C-4A42-A067-752599F0C407

P304

Q37729368-379E812C-52D6-4B97-ABDA-85C677532403

P31

Q37729368-5EC04557-1FBB-408F-8FF7-A8CB42472D9A

P356

Q37729368-BC0B1DEB-A53C-4B1B-BC62-D667BA580C43

P433

Q37729368-5C2B3BF0-6551-47E4-B045-77A30CA1F6B4

P478

Q37729368-69E194DC-7608-4042-B775-124F51F7AB3F

P50

Q37729368-B56297D0-F504-4F6F-A2BD-5F0369DE543F

P577

Q37729368-934F0537-502F-474F-9FF9-11210841AD4D

P5875

Q37729368-75D1F840-AC1A-4A13-826F-63C79CC17A64

P698

Q37729368-E0A4829E-D6C1-4466-B790-D7DE16CE3E2A

P932

Q37729368-BC52A533-7132-4E83-B963-B81E15A1B8F0

P356

P1433

Cellular and Molecular Immunology

P1476

B-cell-targeted therapies in systemic lupus erythematosus

@en

P2093

Chak-Sing Lau

http://www.w3.org/2001/XMLSchema#string

Liwei Lu

http://www.w3.org/2001/XMLSchema#string

Rachel Chun-Yee Tam

http://www.w3.org/2001/XMLSchema#string

Vera Sau-Fong Chan

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Pathogenesis of systemic lupus erythematosus

IL-17 and Th17 Cells

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

P2888

P304

133-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CMI.2012.64

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Helen H L Tsang

P577

2013-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235776066

http://www.w3.org/2001/XMLSchema#string

P698

23455017

http://www.w3.org/2001/XMLSchema#string

P932

4003049

http://www.w3.org/2001/XMLSchema#string